NASDAQ:SRRK Scholar Rock (SRRK) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free SRRK Stock Alerts $13.96 -0.13 (-0.92%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$13.60▼$14.1750-Day Range$13.20▼$17.7652-Week Range$5.56▼$21.17Volume944,363 shsAverage Volume778,945 shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/APrice Target$25.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Scholar Rock alerts: Email Address Scholar Rock MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside80.3% Upside$25.17 Price TargetShort InterestBearish16.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment1.27Based on 2 Articles This WeekInsider TradingSelling Shares$351,931 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.01) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.14 out of 5 starsMedical Sector156th out of 907 stocksBiological Products, Except Diagnostic Industry16th out of 153 stocks 3.6 Analyst's Opinion Consensus RatingScholar Rock has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageScholar Rock has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.30% of the outstanding shares of Scholar Rock have been sold short.Short Interest Ratio / Days to CoverScholar Rock has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in Scholar Rock has recently increased by 1.36%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldScholar Rock does not currently pay a dividend.Dividend GrowthScholar Rock does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreScholar Rock has received a 71.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Scholar Rock is -0.82. Previous Next 2.4 News and Social Media Coverage News SentimentScholar Rock has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Scholar Rock this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for SRRK on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scholar Rock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $351,931.00 in company stock.Percentage Held by Insiders26.20% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Scholar Rock are expected to grow in the coming year, from ($2.01) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scholar Rock is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scholar Rock is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScholar Rock has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Scholar Rock Stock (NASDAQ:SRRK)Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Read More SRRK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRRK Stock News HeadlinesApril 24, 2024 | investorplace.com3 Speculative Weight Loss Drug Stocks to Bet On for Big GainsApril 22, 2024 | americanbankingnews.comScholar Rock Holding Co. (NASDAQ:SRRK) Given Consensus Rating of "Buy" by AnalystsApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 12, 2024 | businesswire.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2024 | finance.yahoo.comSRRK Oct 2024 15.000 putApril 2, 2024 | finance.yahoo.comSRRK Oct 2024 20.000 callMarch 28, 2024 | msn.comStocks See Support from Improved Soft-Landing ProspectsMarch 23, 2024 | seekingalpha.comSRRK Scholar Rock Holding CorporationApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. March 20, 2024 | finance.yahoo.comScholar Rock Holding Corp Reports Full Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comScholar Rock Holding Corp (2QK.BE)March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Scholar Rock on Strong SMA Pipeline and Strategic DevelopmentsMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Scholar Rock Holding on Strong Drug Pipeline Potential and Expansion into Obesity MarketMarch 19, 2024 | investorplace.comSRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023March 19, 2024 | markets.businessinsider.comScholar Rock Reports Wider Loss For Full YearMarch 19, 2024 | businesswire.comScholar Rock Reports Full Year 2023 Financial Results and Highlights Business ProgressMarch 17, 2024 | finance.yahoo.comSRRK Apr 2024 10.000 putMarch 17, 2024 | finance.yahoo.comSRRK Apr 2024 22.500 callMarch 16, 2024 | ca.finance.yahoo.comSRRK Oct 2024 5.000 callMarch 16, 2024 | ca.finance.yahoo.comSRRK Jul 2024 10.000 callMarch 16, 2024 | ca.finance.yahoo.comSRRK Oct 2024 25.000 callMarch 15, 2024 | businesswire.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2024 | finance.yahoo.comSRRK Mar 2024 7.500 putFebruary 28, 2024 | finance.yahoo.comScholar Rock to Participate in Upcoming Investor ConferencesFebruary 28, 2024 | businesswire.comScholar Rock to Participate in Upcoming Investor ConferencesFebruary 21, 2024 | wsj.comScholar Rock Holding Corp.February 17, 2024 | ca.finance.yahoo.comSRRK Mar 2024 15.000 callSee More Headlines Receive SRRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SRRK CUSIPN/A CIK1727196 Webwww.scholarrock.com Phone(857) 259-3860Fax866-493-4935Employees150Year FoundedN/APrice Target and Rating Average Stock Price Target$25.17 High Stock Price Target$30.00 Low Stock Price Target$20.00 Potential Upside/Downside+80.3%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.48% Return on Assets-57.10% Debt Debt-to-Equity Ratio0.22 Current Ratio8.80 Quick Ratio8.80 Sales & Book Value Annual Sales$33.19 million Price / Sales32.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.12 per share Price / Book4.47Miscellaneous Outstanding Shares77,866,000Free Float57,465,000Market Cap$1.09 billion OptionableOptionable Beta0.90 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jay Thomas Backstrom M.D. (Age 69)M.P.H., President, CEO & Director Comp: $686.49kMr. Edward H. Myles MBA (Age 52)CFO, COO & Treasurer Comp: $668.49kMs. Junlin Ho J.D. (Age 45)General Counsel & Corporate Secretary Comp: $563.73kMr. Mo Qatanani Ph.D. (Age 50)Chief Scientific Officer Rushmie NofsingerVice President of Corporate Affairs & Investor RelationsMs. Caryn Parlavecchio (Age 52)Chief Human Resources Officer Ms. Lisa Amaya PriceSenior Vice President of Human ResourcesMs. Erin Moore (Age 49)Senior Vice President of Finance Mr. Ryan IarrobinoSenior Vice President of Clinical Development & OperationsDr. Jing L. Marantz M.B.A. (Age 59)M.D., Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsTarsus PharmaceuticalsNASDAQ:TARSAdaptimmune TherapeuticsNASDAQ:ADAPAutolus TherapeuticsNASDAQ:AUTLVir BiotechnologyNASDAQ:VIR4D Molecular TherapeuticsNASDAQ:FDMTView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 200 shares on 4/25/2024Ownership: 0.000%Fisher Asset Management LLCSold 27,891 shares on 3/5/2024Ownership: 0.157%Wellington Management Group LLPBought 71,640 shares on 3/5/2024Ownership: 0.099%Goldman Sachs Group Inc.Bought 342,690 shares on 3/1/2024Ownership: 1.984%University of Texas Texas AM Investment Managment Co.Bought 28,423 shares on 2/28/2024Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions SRRK Stock Analysis - Frequently Asked Questions Should I buy or sell Scholar Rock stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares. View SRRK analyst ratings or view top-rated stocks. What is Scholar Rock's stock price target for 2024? 6 Wall Street analysts have issued 12 month price objectives for Scholar Rock's shares. Their SRRK share price targets range from $20.00 to $30.00. On average, they predict the company's share price to reach $25.17 in the next year. This suggests a possible upside of 80.3% from the stock's current price. View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts. How have SRRK shares performed in 2024? Scholar Rock's stock was trading at $18.80 on January 1st, 2024. Since then, SRRK stock has decreased by 25.7% and is now trading at $13.96. View the best growth stocks for 2024 here. When is Scholar Rock's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SRRK earnings forecast. How were Scholar Rock's earnings last quarter? Scholar Rock Holding Co. (NASDAQ:SRRK) posted its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.01. What ETF holds Scholar Rock's stock? iShares Neuroscience and Healthcare ETF holds 3,905 shares of SRRK stock, representing 1.58% of its portfolio. What other stocks do shareholders of Scholar Rock own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA). When did Scholar Rock IPO? Scholar Rock (SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Scholar Rock's major shareholders? Scholar Rock's stock is owned by a variety of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include Amir Nashat, Caryn Parlavecchio, Edward H Myles, Jay T Backstrom, Jeffrey S Flier, Junlin Ho, Mo Qatanani, Public Equities LP Invus and Samsara Biocapital Gp, Llc. View institutional ownership trends. How do I buy shares of Scholar Rock? Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SRRK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scholar Rock Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
